Results 211 to 220 of about 232,812 (303)
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
Synchronous Coexistence of JAK2 V617F-Positive Essential Thrombocythemia and IgG Kappa Multiple Myeloma in an Octogenarian Patient: A Case Report. [PDF]
Ribero-Vargas M +3 more
europepmc +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Narrative nursing for prolonged myelosuppression after autologous stem cell transplantation in multiple myeloma: A case report. [PDF]
Huang Q, Jiang M.
europepmc +1 more source
MCL‐1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model
Abstract Background and Purpose Myeloid cell leukaemia‐1 (MCL‐1) is an essential anti‐apoptotic protein and a promising therapeutic target in oncology. Early clinical studies of MCL‐1 inhibitors reported unexpected elevations in cardiac troponin, raising concerns about potential cardiotoxicity.
Markus B. Heckmann +7 more
wiley +1 more source
Plasmacytomas in Extramedullary Manifestation of Multiple Myeloma: A Case Report. [PDF]
Hmayed J +6 more
europepmc +1 more source
From infusion to pills in acute myeloid leukaemia: Reorganizing care beyond the infusion unit
British Journal of Haematology, EarlyView.
Fortunato Morabito +11 more
wiley +1 more source

